COVID-19
The randomized, open-label, multicenter studies will enroll about 1,000 patients mostly in Asia, as well as in countries that have had high numbers of diagnosed cases. The trials are planned to start in March.
Now that global responses are fully mobilized, what is being done to identify and develop drugs and vaccines against this novel coronavirus?
The outbreak of the coronavirus, now called COVID-19, is taking some unexpected twists and turns.
PRESS RELEASES